Paratek Pharmaceuticals Stock Return On Equity
PRTKDelisted Stock | USD 2.18 0.00 0.00% |
Paratek Pharmaceuticals fundamentals help investors to digest information that contributes to Paratek Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Paratek Stock. The fundamental analysis module provides a way to measure Paratek Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Paratek Pharmaceuticals stock.
Paratek |
Paratek Pharmaceuticals Company Return On Equity Analysis
Paratek Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Paratek Pharmaceuticals has a Return On Equity of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The return on equity for all United States stocks is 100.0% lower than that of the firm.
Paratek Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Paratek Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics of similar companies.Paratek Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Paratek Fundamentals
Return On Asset | -0.18 | |||
Profit Margin | (0.35) % | |||
Operating Margin | (0.25) % | |||
Current Valuation | 345.3 M | |||
Shares Outstanding | 57.32 M | |||
Shares Owned By Insiders | 11.70 % | |||
Shares Owned By Institutions | 55.08 % | |||
Number Of Shares Shorted | 2.64 M | |||
Price To Earning | (5.49) X | |||
Price To Sales | 0.86 X | |||
Revenue | 150.79 M | |||
Gross Profit | 99.39 M | |||
EBITDA | (44.9 M) | |||
Net Income | (63.57 M) | |||
Cash And Equivalents | 57.01 M | |||
Cash Per Share | 1.03 X | |||
Total Debt | 258.41 M | |||
Debt To Equity | 3.20 % | |||
Current Ratio | 3.11 X | |||
Book Value Per Share | (3.52) X | |||
Cash Flow From Operations | (66.14 M) | |||
Short Ratio | 6.74 X | |||
Earnings Per Share | (1.11) X | |||
Price To Earnings To Growth | (0.02) X | |||
Target Price | 3.1 | |||
Number Of Employees | 268 | |||
Beta | 1.7 | |||
Market Capitalization | 127.83 M | |||
Total Asset | 172.54 M | |||
Retained Earnings | (930.45 M) | |||
Working Capital | 99.45 M | |||
Current Asset | 127.46 M | |||
Current Liabilities | 21.75 M | |||
Z Score | -6.55 | |||
Net Asset | 172.54 M |
About Paratek Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Paratek Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Paratek Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Paratek Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |